Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...

BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of patients with pretreated HER2 ...

Hamlet Gasoyan, MD, discusses what to know from a study that found there to be disparities in time to treatment with oral antimyeloma medications when used in patients with newly diagnosed multiple ...